Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Recruiting · Phase 3 · NCT07133308
Conditions: Alopecia Areata
At a glance
- Research payments reported, 2025
- $15,250
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 355
About the trial
- Sponsor
- Sun Pharmaceutical Industries, Inc.
- Tested
- Deuruxolitinib (drug), Placebo (drug)
- Dates
- Started 2025-08-05; completion 2028-05
- Results posted
- Not yet
This study evaluates the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair loss.
From ClinicalTrials.gov, last updated 2026-01-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sun Pharmaceutical Industries Inc. reported $15,250 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Elias Research Associates, LLC $15,250
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.